



Clinical trial results:

A randomized, assessor-blinded, multicenter, international study investigating efficacy, patient's acceptance, safety and tolerability of Sodium Phosphate tablets compared to split dose Polyethylene Glycol for colon cleansing prior to colonoscopy.

Summary

| | |
|--------------------------|----------------|
| EudraCT number | 2012-005115-13 |
| Trial protocol | ES |
| Global end of trial date | 06 March 2014 |

Results information

| | |
|--------------------------------|------------------|
| Result version number | v1 (current) |
| This version publication date | 31 December 2016 |
| First version publication date | 31 December 2016 |

Trial information

Trial identification

| | |
|-----------------------|---------|
| Sponsor protocol code | ICOL121 |
|-----------------------|---------|

Additional study identifiers

| | |
|------------------------------------|-------------|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT01840553 |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|--|
| Sponsor organisation name | MAYOLY SPINDLER |
| Sponsor organisation address | 6 avenue de l'europe, chatou, France, 78400 |
| Public contact | Valérie O'Mahony, Mayoly Spindler, 33 0134804102, valerie.omahony@mayoly.com |
| Scientific contact | Valérie O'Mahony, Mayoly Spindler, 33 0134804102, valerie.omahony@mayoly.com |

Notes:

Paediatric regulatory details

| | |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|---------------|
| Analysis stage | Final |
| Date of interim/final analysis | 02 June 2014 |
| Is this the analysis of the primary completion data? | Yes |
| Primary completion date | 06 March 2014 |
| Global end of trial reached? | Yes |
| Global end of trial date | 06 March 2014 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

Assess the efficacy of sodium phosphate tablets versus split dose of 4 liters of PEG for bowel cleansing prior to colonoscopy.

Protection of trial subjects:

Subjects had a follow up visit 7 to 10 days after last study medication intake for safety follow up

Background therapy: -

Evidence for comparator: -

| | |
|---|---------------|
| Actual start date of recruitment | 24 April 2013 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | No |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|-------------|
| Country: Number of subjects enrolled | Spain: 172 |
| Country: Number of subjects enrolled | France: 216 |
| Country: Number of subjects enrolled | Germany: 73 |
| Worldwide total number of subjects | 461 |
| EEA total number of subjects | 461 |

Notes:

Subjects enrolled per age group

| | |
|---|-----|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 390 |
| From 65 to 84 years | 71 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details:

Patients undergoing total colonoscopy for screening or surveillance colonoscopy from April 2013 to March 2014 were selected for inclusion in the study in 3 European countries (France, Germany and Spain).

Pre-assignment

Screening details:

Patients undergoing total colonoscopy were selected, aged from 18 to 75 years, eligible for both treatments, had a normal renal function and no contraindication for sodium phosphate. Overall, inclusion and exclusion criteria were defined according to the SMPC.

Period 1

| | |
|------------------------------|--------------------------------|
| Period 1 title | overall trial (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Single blind |
| Roles blinded | Assessor ^[1] |

Blinding implementation details:

Colonoscopies were video-recorded. Two independent experienced gastroenterologists, blinded for treatment reviewed and scored the quality of the preparation for assessment. For any discrepancies, a third blinded expert determined the BBPS score.

Arms

| | |
|------------------------------|--------------------------|
| Are arms mutually exclusive? | Yes |
| Arm title | Sodium phosphate tablets |

Arm description:

Sodium phosphate tablets

| | |
|--|--------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | sodium phosphate tablets |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Patients received 32 tablets of sodium phosphate bowel preparation (NaP, Colokit©) in total. Each tablet contains monobasic monohydrate sodium phosphate (1102 mg) and dibasic anhydrous sodium phosphate (398 mg).

The evening before the examination, patients took a first sequence : 4 NaP tablets with 250mL of water (or another clear liquid) every 15 minutes, repeated a further 4 times for a total of 20 tablets.

On the day of the examination, patients took the second sequence :4 tablets of NaP every 15 minutes, in addition to 250mL of water (or another clear liquid), repeated another two times under the same conditions, i.e.12 tablets in total.

| | |
|------------------|---------------------|
| Arm title | Polyethylene glycol |
|------------------|---------------------|

Arm description:

Polyethylene glycol

| | |
|--|------------------------------------|
| Arm type | Active comparator |
| Investigational medicinal product name | Polyethylene glycol |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Powder for oral solution in sachet |
| Routes of administration | Oral use |

Dosage and administration details:

Patients received 4 liters of PEG (Klean-Prep®) in total before colonoscopy. Preparation was standardized as follows:

The day before the examination, two sachets were taken during the evening.

The remaining two sachets were taken in the morning of the examination day, starting 4-8 hours prior to the colonoscopy.

Each sachet was dissolved in one liter of water and taken at a rate of 250mL every 10 to 15 minutes.

Notes:

[1] - The roles blinded appear inconsistent with a simple blinded trial.

Justification: patients and investigators were not blinded but the primary efficacy criteria was assessed by blinded assessors (videos of the colonoscopies)

| Number of subjects in period 1^[2] | Sodium phosphate tablets | Polyethylene glycol |
|---|--------------------------|---------------------|
| Started | 226 | 226 |
| Completed | 226 | 218 |
| Not completed | 0 | 8 |
| Consent withdrawn by subject | - | 1 |
| colonoscopy not performed | - | 4 |
| poor compliance | - | 2 |
| Lost to follow-up | - | 1 |

Notes:

[2] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: 461 patients were randomised but only 452 received the study treatments. 9 didn't receive treatment: 4 consent withdrawal, 2 lost of follow up, 2 adverse event and 1 for other reason

Baseline characteristics

Reporting groups

| | |
|-----------------------|---------------|
| Reporting group title | overall trial |
|-----------------------|---------------|

Reporting group description: -

| Reporting group values | overall trial | Total | |
|--|---------------|-------|--|
| Number of subjects | 452 | 452 | |
| Age categorical | | | |
| Units: Subjects | | | |
| In utero | 0 | 0 | |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | |
| Newborns (0-27 days) | 0 | 0 | |
| Infants and toddlers (28 days-23 months) | 0 | 0 | |
| Children (2-11 years) | 0 | 0 | |
| Adolescents (12-17 years) | 0 | 0 | |
| Adults (18-64 years) | 386 | 386 | |
| From 65-84 years | 66 | 66 | |
| 85 years and over | 0 | 0 | |
| Gender categorical | | | |
| Units: Subjects | | | |
| Female | 225 | 225 | |
| Male | 227 | 227 | |

Subject analysis sets

| | |
|----------------------------|---------------|
| Subject analysis set title | Full analysis |
|----------------------------|---------------|

| | |
|---------------------------|---------------|
| Subject analysis set type | Full analysis |
|---------------------------|---------------|

Subject analysis set description:

The Full Analysis Set (FAS) includes all subjects who received any study medication for whom the BBPS score was obtained (primary efficacy endpoint), disregarding any protocol deviation.

| Reporting group values | Full analysis | | |
|--|---------------|--|--|
| Number of subjects | 429 | | |
| Age categorical | | | |
| Units: Subjects | | | |
| In utero | 0 | | |
| Preterm newborn infants (gestational age < 37 wks) | 0 | | |
| Newborns (0-27 days) | 0 | | |
| Infants and toddlers (28 days-23 months) | 0 | | |
| Children (2-11 years) | 0 | | |
| Adolescents (12-17 years) | 0 | | |
| Adults (18-64 years) | 367 | | |
| From 65-84 years | 62 | | |
| 85 years and over | 0 | | |

| | | | |
|--------------------|-----|--|--|
| Gender categorical | | | |
| Units: Subjects | | | |
| Female | 214 | | |
| Male | 215 | | |

End points

End points reporting groups

| | |
|--|--------------------------|
| Reporting group title | Sodium phosphate tablets |
| Reporting group description: | |
| Sodium phosphate tablets | |
| Reporting group title | Polyethylene glycol |
| Reporting group description: | |
| Polyethylene glycol | |
| Subject analysis set title | Full analysis |
| Subject analysis set type | Full analysis |
| Subject analysis set description: | |
| The Full Analysis Set (FAS) includes all subjects who received any study medication for whom the BBPS score was obtained (primary efficacy endpoint), disregarding any protocol deviation. | |

Primary: overall quality of bowel cleansing

| | |
|------------------------|------------------------------------|
| End point title | overall quality of bowel cleansing |
| End point description: | |
| End point type | Primary |
| End point timeframe: | |
| during colonoscopy | |

| End point values | Sodium phosphate tablets | Polyethylene glycol | Full analysis | |
|--|--------------------------|---------------------|----------------------|--|
| Subject group type | Reporting group | Reporting group | Subject analysis set | |
| Number of subjects analysed | 219 | 210 | 429 | |
| Units: number of patients with a BBPS ≥ 7 | 189 | 187 | 376 | |

Statistical analyses

| | |
|--|--|
| Statistical analysis title | primary efficacy analysis |
| Statistical analysis description: | |
| Descriptive statistics [group size, mean, standard deviations, median, ranges, and 95 % confidence intervals (CI)] were used to report patients' baseline characteristics. The sample size was determined assuming an estimated "adequate" cleansing rate of the colon of 85 %, a 10 % non-inferiority margin, 80 % power and a one-sided significance level of 0.025. | |
| Comparison groups | Sodium phosphate tablets v Polyethylene glycol |
| Number of subjects included in analysis | 429 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority ^[1] |
| P-value | < 0.025 |
| Method | Chi-squared |

Notes:

[1] - 10 % non-inferiority margin

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Adverse events were collected from informed consent signature till the follow up visit (7-10 days after last study drug administration)

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|------|
| Dictionary version | 16.1 |
|--------------------|------|

Reporting groups

| | |
|-----------------------|---------------------------|
| Reporting group title | overall Safety population |
|-----------------------|---------------------------|

Reporting group description:

The Safety set includes all the subjects included in the study who received any study medication.

| Serious adverse events | overall Safety population | | |
|---|---------------------------|--|--|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 0 / 452 (0.00%) | | |
| number of deaths (all causes) | 0 | | |
| number of deaths resulting from adverse events | 0 | | |

Frequency threshold for reporting non-serious adverse events: 2 %

| Non-serious adverse events | overall Safety population | | |
|---|---------------------------|--|--|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 298 / 452 (65.93%) | | |
| Nervous system disorders | | | |
| Headache | | | |
| subjects affected / exposed | 11 / 452 (2.43%) | | |
| occurrences (all) | 2 | | |
| General disorders and administration site conditions | | | |
| Hyperphosphataemia | | | |
| subjects affected / exposed | 9 / 452 (1.99%) | | |
| occurrences (all) | 2 | | |
| Gastrointestinal disorders | | | |
| Abdominal distension | | | |

| | | | |
|-----------------------------|--------------------|--|--|
| subjects affected / exposed | 245 / 452 (54.20%) | | |
| occurrences (all) | 54 | | |
| Nausea | | | |
| subjects affected / exposed | 142 / 452 (31.42%) | | |
| occurrences (all) | 31 | | |
| Abdominal pain | | | |
| subjects affected / exposed | 67 / 452 (14.82%) | | |
| occurrences (all) | 15 | | |
| Vomiting | | | |
| subjects affected / exposed | 44 / 452 (9.73%) | | |
| occurrences (all) | 10 | | |
| Gastritis | | | |
| subjects affected / exposed | 12 / 452 (2.65%) | | |
| occurrences (all) | 3 | | |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported

Online references

<http://www.ncbi.nlm.nih.gov/pubmed/27864718>